Publications by authors named "Hugo Arlegui"

Claim this Profile
C
Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort.
Romain Salle, Florence Tubach, Hugo Arlegui, Raphaëlle Curmin, Manuelle Viguier

Clin Exp Dermatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry.
Helene Aubert, Hugo Arlegui, Yann De Rycke, Herve Bachelez, Marie Beylot-Barry

Br J Dermatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort.
Thomas Bettuzzi, Hervé Bachelez, Marie Beylot-Barry, Hugo Arlégui, Carle Paul

Acta Derm Venereol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.
Florence Assan, Florence Tubach, Hugo Arlegui, Manuelle Viguier, Marie Beylot-Barry

Dermatology· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines.
Hugo Arlegui, Kaatje Bollaerts, Francesco Salvo, Vincent Bauchau, Gaëlle Nachbaur

Drug Saf· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC).
Hugo Arlegui, Kaatje Bollaerts, Vincent Bauchau, Gaëlle Nachbaur, Bernard Bégaud

Drug Saf· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit-Risk Models: The Example of Rotavirus Vaccination in France.
Hugo Arlegui, Gaëlle Nachbaur, Nicolas Praet, Bernard Bégaud, J Jaime Caro

Clin Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review.
Hugo Arlegui, Gaëlle Nachbaur, Nicolas Praet, Bernard Bégaud

Open Forum Infect Dis· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis.
Edouard Ledent, Hugo Arlegui, Hubert Buyse, Peter Basile, Naveen Karkada

BioDrugs· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis